Validation of the Smart Mask V1 System and Its Measurements of SpO2 and Pulse Rate

Last updated: August 13, 2025
Sponsor: Pathway Medtech, LLC.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sleep Disorders

Sleep Apnea Syndromes

Treatment

Smart Mask V1 System

Clinical Study ID

NCT07086742
TP-SMS-0004
CIV-24-10-049534
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical study is to investigate a new medical device, the Smart Mask V1 System (herein 'Smart Mask'), and particularly its measurements of blood oxygen levels (SpO2) and pulse rate (PR) in healthy adults aged 18 to 65.

More specifically, the study is directed at answering the following questions:

  • Can the Smart Mask accurately measure SpO2 levels compared to established reference devices (reference oximeters, blood gas) throughout the range of SpO2 ~ 70 - 100%?

  • Can the Smart Mask accurately measure PR during the same conditions?

  • Does skin pigmentation impact the accuracy of Smart Mask's measurements of SpO2 and PR.

The following reference devices will be used in the study:

  • An FDA-cleared fingertip pulse oximeter (Nellcor Portable SpO2 Patient Monitoring System, PM10N)

  • A laboratory-grade CO-oximeter (Radiometer ABL90 FLEX) that analyzes oxygen saturation from blood samples.

Study participants will:

  • Wear the Smart Mask on their face and a fingertip pulse oximeter while lying down

  • Breathe air with gradually reduced oxygen levels inside a specialized hypoxia room while being closely.

  • In a second phase of the study, have a catheter inserted into a wrist artery for blood sampling to directly measure oxygen levels with the CO-oximeter.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy subjects with ASA health score of I or II

  • Subjects aged between ≥ 18 and ≤ 65 years.

  • Subjects who have provided informed consent and are willing to comply with the studyprocedures.

Exclusion

Exclusion Criteria:

  • Heavy smokers or individuals exposed to high levels of carbon monoxide resulting inelevated carboxyhemoglobin levels.

  • Individuals with conditions that result in elevated methemoglobin levels.

  • Individuals with hypoxia (SpO2 < 95% at 21% O2).

  • Severe claustrophobia.

  • Subjects known with altitude sickness.

  • Subjects who are obese (BMI ≥ 35 kg/m2).

  • Subjects with a known history of moderate to severe heart, lung, kidney or liverdisease.

  • Subjects diagnosed with moderate to severe asthma.

  • Subjects with a hemoglobinopathy or history of anemia, e.g. sickle cell anemia,thalassemia, that in the investigator's opinion, would make them unsuitable forstudy participation.

  • Subjects with any other serious systemic illness.

  • Any injury, deformity, or abnormality at the sensor sites that, in theinvestigator's opinion, would interfere with the correct functioning of the test orreference devices.

  • Subjects with a history of fainting or vasovagal response.

  • Subjects with a history of sensitivity or allergy to local anesthetics ordisinfectants if included in the IN study.

  • Subjects diagnosed with Raynaud's disease.

  • Subjects with unacceptable collateral circulation based on examination by theinvestigator.

  • Subjects who are pregnant, lactating or trying to become pregnant.

  • Subjects unable or unwilling to provide informed consent or comply with studyprocedures.

  • Subjects with any other condition that, in the investigator's opinion, would makethem unsuitable for the study.

  • Subjects who refuse to remove nail polish from their index finger.

  • Volunteers not willing to remove facial make-up.

Study Design

Total Participants: 36
Treatment Group(s): 1
Primary Treatment: Smart Mask V1 System
Phase:
Study Start date:
September 01, 2025
Estimated Completion Date:
December 31, 2025

Study Description

This clinical study evaluates the Smart Mask V1 System, a medical device designed to measure blood oxygen saturation (SpO2) and pulse rate (PR) using reflective photoplethysmography (PPG) sensors integrated into a face mask intended for use with positive airway pressure (PAP) therapy. The study aims to validate the accuracy of the Smart Mask's optical measurements under controlled, progressive hypoxia conditions in healthy adult volunteers.

The investigation is divided into two sequential phases; Non-Invasive (NI) and Invasive (IN) Study. All study sessions are conducted at the Complementary Medical Centre (CMC) in Genk, Belgium, within a certified normobaric hypoxia room. This room is sealed and climate-controlled, equipped with oxygen and carbon dioxide sensors to maintain a stable and safe hypoxic environment.

Hypoxia is induced gradually to reduce any discomfort or potential risk to participants. Comprehensive safety protocols are in place to protect volunteers. These include medical screening and obtaining informed consent prior to enrollment, as well as real-time monitoring by trained medical staff throughout the exposure. Immediate exit protocols are activated if a participant's SpO2 falls below 73% or if symptoms of acute mountain sickness are observed. Emergency oxygen and resuscitation equipment are readily available on-site. Additionally, participants are reminded that they may withdraw from the study at any time without penalty.

Connect with a study center

  • Complementair Medisch Centrum (CMC) Europe

    Genk, 3600
    Belgium

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.